SCHEMBL930356

SCHEMBL930356

O=C1c2ccccc2C(=O)N1Cc1ncccc1CO

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
MEN1 O00255 1/20 0.54
PKM P14618 1/20 0.54
KMT2A Q03164 1/20 0.54
GRM5 P41594 7/20 0.50
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
POLB P06746 1/20 0.42
TSHR P16473 1/20 0.42
KDM4E B2RXH2 1/20 0.42
TP53 P04637 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CYP1B1 Q16678 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL928872 0.81 MEN1 (0.50) ALDH1A1MEN1PKMKMT2AGRM5
SCHEMBL1632864 0.79 ALDH1A1 (0.54) ALDH1A1MEN1PKMKMT2AGRM5
SCHEMBL7987177 0.79 CASP3 (0.49) ALDH1A1MEN1PKMKMT2AGRM5
Hydrochloric Acid SCHEMBL1630784 0.78 ALDH1A1 (0.53) ALDH1A1MEN1PKMKMT2AGRM5
SCHEMBL4105385 0.75 GRM5 (0.53) ALDH1A1MEN1PKMKMT2AGRM5
SCHEMBL1632994 0.75 ALDH1A1 (0.57) ALDH1A1MEN1PKMKMT2AGRM5
SCHEMBL12725681 0.75 MEN1 (0.57) ALDH1A1MEN1PKMKMT2AGRM5
Bromide SCHEMBL1630273 0.74 ALDH1A1 (0.55) ALDH1A1MEN1PKMKMT2AGRM5
SCHEMBL19067176 0.74 ALDH1A1 (0.51) ALDH1A1MEN1PKMKMT2AMAPK1
SCHEMBL29843133 0.73 ALDH1A1 (0.68) ALDH1A1MEN1PKMKMT2AGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7875600-B2 Pyrimidine compounds as purine receptor antagonist VERNALIS (R&D) LIMITED (GB) 2011-01-25 US disclosed
US-20070281936-A1 To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide VERNALIS (R & D ) LIMITED (GB) 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281936-A1 To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide ADORA2A, ADORA3, ADORA1 ALDH1A1 562/4885MEN1 4622/4885PKM 1856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.